MKMin-Jung Kwon

Min-Jung Kwon

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Min-Jung Kwon has a total of 39 co-authors. Here are the top co-authors by number of shared publications:

  • Hocheol Shin

    Department of Family Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Korea

    2 shared publications
  • Seungho Ryu

    Center for Cohort Studies, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea

    2 shared publications
  • Yoosoo Chang

    Center for Cohort Studies, Total Healthcare Center, Kangbuk Samsung Hospital Sungkyunkwan University School of Medicine, Seoul, South Korea

    2 shared publications
  • Bomi Kim

    Division of Infectious Diseases, Department of Internal Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul 03181, Republic of Korea

    1 shared publication
  • Byoungduck Han

    Department of Family Medicine, Korea University Anam Hospital, Korea University College of Medicine

    1 shared publication
  • Byung-Seong Suh

    Department of Occupational and Environmental Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Korea

    1 shared publication

Latest Publications

  • Open Access

    Blood viscosity as a continuous marker of cardio-metabolic risk burden: a large-scale cross-sectional study of 38,574 adults

    by Dayeon Lee, Byoungduck Han, Hongyup Ahn, Eunhye Cho, Minjung Kwon, Cheolyoung Park

    Aims: Metabolic syndrome (MetS) is diagnosed using fixed thresholds that may not fully reflect the continuous accumulation of cardio-metabolic risk. We investigated whether whole blood viscosity (WBV) increases progressively with increasing MetS burden and explored the relative contribution of individual MetS components to hemorheologic alterations. Methods: We analyzed 38,574 adults (21,914 men and 16,660 women) who underwent comprehensive health examinations between January and April 2021. Whole blood viscosity was measured by cone-plate viscometry at shear rates of 300 s -1 (systolic blood viscosity [SBV]) and 5 s -1 (diastolic blood viscosity [DBV]). MetS was defined according to NCEP-ATP III criteria. Associations between WBV and MetS burden were evaluated using logistic regression, ANCOVA, regression tree analyses, ROC analyses, and sex-by-viscosity interaction testing. Results: WBV increased progressively with each additional MetS component in both sexes (p for trend <0.001). After full adjustment for hematocrit, age, smoking status, eGFR, white blood cell count, and AST/ALT, higher SBV was associated with MetS in both women (OR 1.45, 95% CI 1.32–1.58, per 1-SD increase) and men (OR 1.27, 95% CI 1.22–1.33, per 1-SD increase). Regression tree analyses identified triglycerides and waist circumference as metabolic factors associated with elevated WBV. Sex-stratified analyses demonstrated a stronger association between WBV and MetS in women than in men. Conclusions: WBV increased in parallel with accumulating cardio-metabolic risk burden, including among individuals who did not meet diagnostic criteria for MetS. WBV may serve as a complementary marker associated with metabolic risk burden, particularly among women and individuals with hypertriglyceridemia or central adiposity.

  • Open Access

    HLA-DPB1*05:01 and HLA-A*11:01 Is Associated with Adverse Drug Reactions to Isoniazid and Rifampin for Treatment of Latent Tuberculosis Infection in South Korea

    by Bomi Kim, Jungok Kim, Sun-Young Yoon, Hae Suk Cheong, Min-Jung Kwon, Joon-Sup Yeom, Han-Na Kim, Eun-Jeong Joo

    Background: Screening and treating healthcare workers (HCWs) for latent tuberculosis infection (LTBI) are essential for tuberculosis (TB) infection control. Adverse drug reactions (ADRs) to anti-TB drugs present challenges to patient safety and treatment completion. Objective: This study investigated the association between human leukocyte antigen (HLA) alleles and the risk of ADRs, especially drug hypersensitivity (DHS) and hepatotoxicity, in HCWs with LTBI receiving isoniazid (INH) and rifampin (RIF) therapy. Methods: Korean HCWs with LTBI who received a 3 month INH and RIF regimen were included in this study. HLA genotyping was performed on HCWs who experienced ADRs during treatment, as well as the control group consisted of individuals who did not develop ADRs. Results: Of the 67 patients, 29 (43.2%) experienced ADRs during INH and RIF therapy. The HLA-A*11:01 allele was more frequent in patients with DHS without hepatotoxicity (DSH+/H−) compared to the control group (DHS−/H−) (4/9, 44.4% vs. 3/38, 7.9%; odd ratio [OR], 8.554; 95% confidence interval [CI], 1.415–59.869; p = 0.018). Conversely, HLA-DPB1*05:01 was associated with an increased risk of hepatotoxicity regardless of DHS (10/20, 50% vs. 5/38, 13.2%; OR, 5.323; 95% CI, 1.493–21.518; p = 0.011). In the DHS with hepatotoxicity group (DHS+/H+), HLA-DPB1*05:01 was present in a higher proportion (3/5, 60% vs. 5/38, 13.2%; OR, 8.912; 95% CI, 1.110–92.993; p = 0.037), whereas HLA-A*11:01 was not observed in this group. Conclusions: The HLA-A*11:01 allele was associated with an increased risk of DHS without hepatotoxicity, whereas the HLA-DPB1*05:01 allele was associated with an increased risk of hepatotoxicity.


  • Open Access

    The Association of Carbohydrate Antigen (CA) 19-9 Levels and Low Skeletal Muscle Mass in Healthy Adults

    by Jae Hyun Lee, Dong-Kun Kim, Mi-Yeon Lee, Han-Sol Lim, Min-Jung Kwon, Yong-Taek Lee, Kyung Jae Yoon, Chul-Hyun Park

    Carbohydrate antigen 19-9 (CA 19-9) is a commonly used tumor marker for pancreatic cancer. However, CA 19-9 can be overexpressed in several benign inflammatory diseases. We investigated the relationship between high CA 19-9 level and low muscle mass (LMM) in healthy adults without cancer. Participants who underwent evaluation of muscle mass and CA 19-9 were included. Exclusion criteria were any malignancy, cardiovascular disease, tuberculosis, and chronic lung/liver disease. Participants were classified into “normal”, “mild LMM”, and “severe LMM” groups based on the skeletal muscle mass index. Multivariable logistic regression analyses were conducted to assess the association of high CA 19-9 with muscle mass status. A total of 263,061 adults were included. The mean age and SMI were 41.03 years and 7.13 kg/m2. After adjustments for various confounders, high CA 19-9 was independently associated with mild LMM (adjusted odds ratio, 1.677 [95% confidence interval, 1.533–1.834]) and severe LMM (2.651 [2.126–3.306]) compared to the normal group. Furthermore, the association between high CA 19-9 and severe LMM was stronger in men than in women. Elevated CA 19-9 levels were independently associated with a higher prevalence of LMM in healthy adults without cancer. Therefore, increased CA 19-9 could be utilized as a novel biomarker for sarcopenia.


  • Open Access

    Hepatitis B virus infection and development of chronic kidney disease: a cohort study

    by Yun Soo Hong, Seungho Ryu, Yoosoo Chang, Miguel Caínzos-Achirica, Min-Jung Kwon, Di Zhao, Tariq Shafi, Mariana Lazo, Roberto Pastor-Barriuso, Hocheol Shin, et al.

    The effect of chronic hepatitis B virus (HBV) infection on the risk of chronic kidney disease (CKD) is controversial. We examined the prospective association between hepatitis B surface antigen (HBsAg) serology status and incident CKD in a large cohort of men and women. Cohort study of 299,913 adults free of CKD at baseline who underwent health screening exams between January 2002 and December 2016 in South Korea. Incident CKD was defined as the development of an estimated glomerular filtration rate (eGFR) < 60 ml/min/1.73m2 and/or proteinuria. Over 1,673,701 person-years of follow-up, we observed 13,924 incident cases of CKD (3225 cases of eGFR < 60 ml/min/1.73m2 and 11,072 cases of proteinuria). In fully adjusted models comparing positive to negative HBsAg participants, the hazard ratio (HR, 95% confidence interval) for incident CKD was 1.11 (1.03–1.21; P = 0.01). The corresponding HR for incident proteinuria and for eGFR < 60 ml/min/1.73m2 were 1.23 (1.12–1.35; P < 0.001) and 0.89 (0.73–1.07; P = 0.21), respectively. The associations were similar across categories of liver enzyme levels at baseline. In this large cohort, HBsAg positive serology was associated with higher risk of incident CKD, and we provide novel evidence that this association was due to a higher incidence of proteinuria in HBsAg positive participants. Our study adds to the growing body of evidence suggesting that chronic HBV infection may be a contributor to the increasing incidence of CKD.


  • Open Access

    Bidirectional Association between Nonalcoholic Fatty Liver Disease and Gallstone Disease: A Cohort Study

    by Yoosoo Chang, Yoo-Hun Noh, Byung-Seong Suh, Yejin Kim, Eunju Sung, Hyun-Suk Jung, Chan-Won Kim, Min-Jung Kwon, Kyung Eun Yun, Jin-Won Noh, et al.

    Nonalcoholic fatty liver disease (NAFLD) and gallstone disease (GD) are often found to coexist but the sequential relationship of NAFLD and GD to each other remains controversial. We prospectively evaluated the bidirectional relationship of NAFLD with GD. A cohort study was performed on Korean adults who underwent a health checkup and were followed annually or biennially for a mean of 6.0 years. Fatty liver and gallstones were diagnosed by ultrasound. NAFLD was defined as hepatic steatosis on ultrasonography in the absence of excessive alcohol use or other identifiable causes. The NAFLD severity was determined by non-invasive fibrosis markers. Among 283,446 participants without either gallstones or cholecystectomy at baseline, 6440 participants developed gallstones. Among 219,641 participants without NAFLD at baseline, 49,301 participants developed NAFLD. The multivariable-adjusted hazard ratio (95% confidence interval) for incident gallstone comparing the NAFLD group vs. the non-NAFLD group was 1.26 (1.17–1.35). Increased non-invasive fibrosis markers of NAFLD were positively associated with an increased incidence of gallstones in a graded and dose-responsive manner (p-trend < 0.01). The multivariable-adjusted hazard ratios (95% confidence intervals) for incident NAFLD comparing gallstone and cholecystectomy to no GD were 1.14 (1.07–1.22) and 1.17 (1.03–1.33), respectively. This large-scale cohort study of young and middle-aged individuals demonstrated a bidirectional association between NAFLD and GD. NAFLD and its severity were independently associated with an increased incidence of gallstones, while GD and cholecystectomy were also associated with incident NAFLD. Our findings indicate that the conditions may affect each other, requiring further studies to elucidate the potential mechanisms underlying this association.